Insider Selling: Natera, Inc. (NASDAQ:NTRA) CEO Sells 6,702 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 6,702 shares of Natera stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $146.03, for a total value of $978,693.06. Following the sale, the chief executive officer now directly owns 203,354 shares in the company, valued at $29,695,784.62. This trade represents a 3.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Wednesday, March 5th, Steven Leonard Chapman sold 87,272 shares of Natera stock. The shares were sold at an average price of $143.40, for a total transaction of $12,514,804.80.
• On Wednesday, January 29th, Steven Leonard Chapman sold 13,685 shares of Natera stock. The stock was sold at an average price of $165.87, for a total transaction of $2,269,930.95.
• On Wednesday, January 22nd, Steven Leonard Chapman sold 78,553 shares of Natera stock. The shares were sold at an average price of $164.97, for a total transaction of $12,958,888.41.

Natera Stock Performance

NTRA stock opened at $149.63 on Friday. The firm has a market cap of $20.23 billion, a price-to-earnings ratio of -85.02 and a beta of 1.80. Natera, Inc. has a twelve month low of $83.13 and a twelve month high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The business’s fifty day simple moving average is $161.71 and its two-hundred day simple moving average is $149.27.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. The company had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of NTRA. Apollon Wealth Management LLC bought a new stake in Natera during the 3rd quarter valued at $270,000. KBC Group NV raised its holdings in shares of Natera by 15.7% in the third quarter. KBC Group NV now owns 3,227 shares of the medical research company’s stock valued at $410,000 after acquiring an additional 439 shares in the last quarter. CIBC Asset Management Inc lifted its stake in Natera by 3.3% in the third quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company’s stock worth $441,000 after acquiring an additional 111 shares during the period. Natixis Advisors LLC grew its holdings in Natera by 26.3% during the 3rd quarter. Natixis Advisors LLC now owns 31,051 shares of the medical research company’s stock worth $3,942,000 after acquiring an additional 6,467 shares in the last quarter. Finally, Thrivent Financial for Lutherans increased its position in Natera by 1.2% during the 3rd quarter. Thrivent Financial for Lutherans now owns 143,903 shares of the medical research company’s stock valued at $18,269,000 after purchasing an additional 1,685 shares during the period. Institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

NTRA has been the subject of a number of research analyst reports. Piper Sandler raised their price objective on Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. The Goldman Sachs Group lifted their price objective on Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a research note on Tuesday, January 28th. Robert W. Baird increased their target price on Natera from $183.00 to $188.00 and gave the company an “outperform” rating in a research report on Friday, February 28th. Sanford C. Bernstein boosted their price target on shares of Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th. Finally, Guggenheim increased their price objective on shares of Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 17th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.